JTT-551, a novel developed PTP1B inhibitor, shows not only an improvement of glucose metabolism but also an antiobesity effect possibly by enhancement of leptin signaling and could be useful in the treatment of type 2 diabetes mellitus and obesity. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.